Cargando…
Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein
Vivax malaria is a major cause of morbidity and mortality worldwide, with several million clinical cases per year and 2.5 billion at risk of infection. A vaccine is urgently needed but the most advanced malaria vaccine, VMP001, confers only very low levels of protection against vivax malaria challen...
Autores principales: | Atcheson, Erwan, Reyes-Sandoval, Arturo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408485/ https://www.ncbi.nlm.nih.gov/pubmed/32402755 http://dx.doi.org/10.1016/j.vaccine.2020.03.063 |
Ejemplares similares
-
A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development
por: Atcheson, Erwan, et al.
Publicado: (2021) -
Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax
Publicado: (1982) -
Chimeric Plasmodium falciparum parasites expressing Plasmodium vivax circumsporozoite protein fail to produce salivary gland sporozoites
por: Marin-Mogollon, Catherin, et al.
Publicado: (2018) -
Genetic polymorphism and natural selection of circumsporozoite protein in Myanmar Plasmodium vivax
por: Võ, Tuấn Cường, et al.
Publicado: (2020) -
Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein
por: Marques, Rodolfo F., et al.
Publicado: (2020)